NFκB and MHC-1 Interplay in Neuroblastoma and Immunotherapy

Lotte Spel; Ariën Schiepers; Marianne Boes

doi:10.1016/j.trecan.2018.09.006

NFκB and MHC-1 Interplay in Neuroblastoma and Immunotherapy

Trends Cancer. 2018 Nov;4(11):715-717. doi: 10.1016/j.trecan.2018.09.006. Epub 2018 Oct 9.

Authors

Lotte Spel¹, Ariën Schiepers¹, Marianne Boes²

Affiliations

¹ Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
² Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Electronic address: [email protected].

PMID: 30352674
DOI: 10.1016/j.trecan.2018.09.006

Abstract

Pediatric neuroblastoma tumors are notorious nonimmunogenic cancers. In contrast to adult tumor types, neuroblastoma cells express low MHC-1, a derivative of its embryonic cell origin expressing little MHC-1. We here address the role of the nuclear factor kappa B (NFκB) pathway in controlling MHC-1 expression in embryonic neural crest cells, during differentiation of healthy cells, and in neuroblastoma tumors. Implications for immunotherapy are discussed.

Keywords: MHC-1; immunotherapy; neural crest; neuroblastoma; nuclear factor kappa B.

MeSH terms

Histocompatibility Antigens Class I / immunology*
Humans
Immunotherapy*
NF-kappa B / immunology*
Neuroblastoma / immunology*
Neuroblastoma / therapy*

Substances

Histocompatibility Antigens Class I
NF-kappa B